4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Expression of Cyclin E1 in hepatic stellate cells is critical for the induction and progression of liver fibrosis and hepatocellular carcinoma in mice

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hepatocellular carcinoma (HCC) is one of the most severe malignancies with increasing incidence and limited treatment options. Typically, HCC develops during a multistep process involving chronic liver inflammation and liver fibrosis. The latter is characterized by the accumulation of extracellular matrix produced by Hepatic Stellate Cells (HSCs). This process involves cell cycle re-entry and proliferation of normally quiescent HSCs in an ordered sequence that is highly regulated by cyclins and associated cyclin-dependent kinases (CDKs) such as the Cyclin E1 (CCNE1)/CDK2 kinase complex. In the present study, we examined the role of Cyclin E1 ( Ccne1) and Cdk2 genes in HSCs for liver fibrogenesis and hepatocarcinogenesis. To this end, we generated conditional knockout mice lacking Ccne1 or Cdk2 specifically in HSCs ( Ccne1 ∆HSC or Cdk2 ∆HSC). Ccne1 ∆HSC mice showed significantly reduced liver fibrosis formation and attenuated HSC activation in the carbon tetrachloride (CCl 4) model. In a combined model of fibrosis-driven hepatocarcinogenesis, Ccne1 ∆HSC mice revealed decreased HSC activation even after long-term observation and substantially reduced tumor load in the liver when compared to wild-type controls. Importantly, the deletion of Cdk2 in HSCs also resulted in attenuated liver fibrosis after chronic CCl 4 treatment. Single-cell RNA sequencing revealed that only a small fraction of HSCs expressed Ccne1/ Cdk2 at a distinct time point after CCl 4 treatment. In summary, we provide evidence that Ccne1 expression in a small population of HSCs is sufficient to trigger extensive liver fibrosis and hepatocarcinogenesis in a Cdk2-dependent manner. Thus, HSC-specific targeting of Ccne1 or Cdk2 in patients with liver fibrosis and high risk for HCC development could be therapeutically beneficial.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: found
          • Article: not found

          Hepatocellular carcinoma

          Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. Infection by hepatitis B virus and hepatitis C virus are the main risk factors for HCC development, although non-alcoholic steatohepatitis associated with metabolic syndrome or diabetes mellitus is becoming a more frequent risk factor in the West. Moreover, non-alcoholic steatohepatitis-associated HCC has a unique molecular pathogenesis. Approximately 25% of all HCCs present with potentially actionable mutations, which are yet to be translated into the clinical practice. Diagnosis based upon non-invasive criteria is currently challenged by the need for molecular information that requires tissue or liquid biopsies. The current major advancements have impacted the management of patients with advanced HCC. Six systemic therapies have been approved based on phase III trials (atezolizumab plus bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib and ramucirumab) and three additional therapies have obtained accelerated FDA approval owing to evidence of efficacy. New trials are exploring combination therapies, including checkpoint inhibitors and tyrosine kinase inhibitors or anti-VEGF therapies, or even combinations of two immunotherapy regimens. The outcomes of these trials are expected to change the landscape of HCC management at all evolutionary stages.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Molecular and cellular mechanisms of liver fibrosis and its regression

            Chronic liver injury leads to liver inflammation and fibrosis, through which activated myofibroblasts in the liver secrete extracellular matrix proteins that generate the fibrous scar. The primary source of these myofibroblasts are the resident hepatic stellate cells. Clinical and experimental liver fibrosis regresses when the causative agent is removed, which is associated with the elimination of these activated myofibroblasts and resorption of the fibrous scar. Understanding the mechanisms of liver fibrosis regression could identify new therapeutic targets to treat liver fibrosis. This Review summarizes studies of the molecular mechanisms underlying the reversibility of liver fibrosis, including apoptosis and the inactivation of hepatic stellate cells, the crosstalk between the liver and the systems that orchestrate the recruitment of bone marrow-derived macrophages (and other inflammatory cells) driving fibrosis resolution, and the interactions between various cell types that lead to the intracellular signalling that induces fibrosis or its regression. We also discuss strategies to target hepatic myofibroblasts (for example, via apoptosis or inactivation) and the myeloid cells that degrade the matrix (for example, via their recruitment to fibrotic liver) to facilitate fibrosis resolution and liver regeneration.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Fate-tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its etiology

              Although organ fibrosis causes significant morbidity and mortality in chronic diseases, the lack of detailed knowledge about specific cellular contributors mediating fibrogenesis hampers the design of effective anti-fibrotic therapies. Different cellular sources including tissue-resident and bone marrow-derived fibroblasts, pericytes and epithelial cells have been suggested to give rise to myofibroblasts, but their relative contributions remain controversial, with profound differences between organs and different diseases. Here we employ a novel Cre-transgenic mouse that marks 99% of hepatic stellate cells (HSCs), a liver-specific pericyte population, to demonstrate that HSCs give rise to 82-96% of myofibroblasts in models of toxic, cholestatic and fatty liver disease. Moreover, we exclude that HSCs function as facultative epithelial progenitor cells in the injured liver. On the basis of these findings, HSCs should be considered the primary cellular target for anti-fibrotic therapies across all types of liver disease.
                Bookmark

                Author and article information

                Contributors
                cliedtke@ukaachen.de
                Journal
                Cell Death Dis
                Cell Death Dis
                Cell Death & Disease
                Nature Publishing Group UK (London )
                2041-4889
                24 August 2023
                24 August 2023
                August 2023
                : 14
                : 8
                : 549
                Affiliations
                [1 ]GRID grid.412301.5, ISNI 0000 0000 8653 1507, Department of Medicine III, , University Hospital RWTH Aachen, ; Aachen, Germany
                [2 ]GRID grid.6363.0, ISNI 0000 0001 2218 4662, Charité - Universitätsmedizin Berlin, Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, ; Berlin, Germany
                [3 ]GRID grid.412301.5, ISNI 0000 0000 8653 1507, Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), , University Hospital RWTH Aachen, ; Aachen, Germany
                [4 ]GRID grid.4795.f, ISNI 0000 0001 2157 7667, Department of Immunology, Ophthalmology and ENT, , Complutense University School of Medicine, ; Madrid, Spain
                [5 ]GRID grid.452391.8, ISNI 0000 0000 9737 4092, DWI – Leibniz Institute for Interactive Materials, ; Aachen, Germany
                [6 ]GRID grid.1957.a, ISNI 0000 0001 0728 696X, Institute of Technical and Macromolecular Chemistry, , RWTH Aachen University, ; Aachen, Germany
                Author information
                http://orcid.org/0000-0001-9793-5862
                http://orcid.org/0000-0002-4360-5785
                http://orcid.org/0000-0001-5594-3055
                http://orcid.org/0000-0003-3888-0931
                http://orcid.org/0000-0003-1516-9610
                http://orcid.org/0000-0003-2762-8247
                http://orcid.org/0000-0003-4681-7887
                Article
                6077
                10.1038/s41419-023-06077-4
                10449804
                37620309
                d69c0c54-ef7e-4f22-a769-4bda863e8931
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 18 January 2023
                : 7 August 2023
                : 16 August 2023
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100001659, Deutsche Forschungsgemeinschaft (German Research Foundation);
                Award ID: CRC1382, 403224013, A02
                Award ID: LI1045/4-2, 271777553
                Award ID: GRK2375, 331065168
                Award ID: GRK2375, 331065168
                Award ID: SFB1382- 403224013, B05
                Award ID: CRC1382, 403224013, A02
                Award ID: BA6226/2-1
                Award ID: SFB1382- 403224013, A08
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/501100010890, CSC | Chinese Government Scholarship;
                Award ID: 202008320329
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/100008672, Wilhelm Sander-Stiftung (Wilhelm Sander Foundation);
                Award ID: No. 2018.129.1
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/501100002347, Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research);
                Award ID: 16LW0143
                Award Recipient :
                Funded by: COST Action Mye-InfoBank 476, Grant No. CA20117
                Funded by: START program of the Medicine Faculty of the RWTH Aachen, Grant No. 118/19
                Categories
                Article
                Custom metadata
                © Associazione Differenziamento e Morte Cellulare ADMC 2023

                Cell biology
                dna synthesis,liver cancer
                Cell biology
                dna synthesis, liver cancer

                Comments

                Comment on this article